key: cord-0850661-sm4pc8i4
authors: Abdulrab, Saleem; Alkadasi, Baleegh; Al-maweri, Sadeq; Halboub, Esam; Alhadainy, Hatem; Geerts, Greta
title: Statins-based prophylactic mouthwash and nasal spray may protect against COVID-19
date: 2020-09-02
journal: New Microbes New Infect
DOI: 10.1016/j.nmni.2020.100751
sha: 700e99a4a94c2761581094a9f6200c85a4b4b061
doc_id: 850661
cord_uid: sm4pc8i4

nan

The novel coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused an unprecedented healthcare crisis. By the date of writing this report, the pandemic has affected more than 20 million people and caused more than 740,000 associated deaths worldwide.

SARS-CoV-2 gets access into the human body mainly through the nose and, to less extent, through the mouth. The virus invades these nasal and oral mucosal cells, mainly through angiotensin-converting enzyme 2 (ACE2) receptors. Within the next days of the disease, the virus progresses downward the pulmonary system triggering mostly mild respiratory symptoms, but it may trigger an intense inflammatory host response, sometimes leading to a life-threatening acute respiratory distress syndrome (ARDS), in a fraction of cases [1]. It is obvious by now that SARS-CoV-2 resides in the nasal and oral mucosal cells [1] rendering these anatomical areas sources of seeding the lower airways and progression of pulmonary disease, and serve as main routes and reservoirs for aerosolized transmission of the viral particles to the external environment [2] . Healthcare workers, especially dentists and otolaryngologists, are at highest risk of getting the infection through droplets transmission or direct contact. In addition, WHO states that airborne transmission may be possible in specific circumstances and settings in which procedures that generate aerosols are performed.

In dental settings, any dental procedure that can aerosolize contaminated saliva can significantly increase airborne contamination with microorganisms. All dental procedures involving the use of hand-pieces and air-water syringes produce aerosols and splatter resulting in exposing the clinicians, dental assistants and patients to a higher risk of being infected, and/or rendering them sources of infection transmission.

We hypothesize that using a statins-based prophylactic mouthwash will reduce COVID-19 transmission in dental settings.

The statin family of drugs represents safe and effective therapeutic agents indicated mainly to reduce cholesterol biosynthesis in the liver, and hence the levels of lowdensity lipoprotein cholesterol (LDL-C) [3] . Apart from this main pharmacologic property, statins have been shown to have antimicrobial, antiviral, antifungal, antiinflammatory, immunomodulatory, and antioxidant properties [4] . More specifically, several studies showed that statin inhibits Zika, Ebola, dengue, Influenza viruses and cytomegalovirus [4, 5] . There are many mechanisms (pathways) that may explain the Secondly, statins are believed to destabilize the lipid rafts, which constitute important packets for the virus replication [6] . Thirdly, statins have shown to interfere with ACE2 signaling and promote ACE2 up-regulation, and thus reversing the action of SARS-CoV-2 [7] .

A recent report based on molecular docking analysis showed that statins might inhibit SARS-CoV-2 entry into host cells via direct binding to its main protease [8] .

Moreover, a more recent study, demonstrated that in-hospital systemic use of statins is associated with a reduced risk of mortality among Covid-19 patients [9] .

From a dental perspective, several in-vitro studies showed promising antibacterial effects of statins against periodontal pathogens [10, 11] . One meta-analysis indicated that statins significantly improved periodontal parameters when used as sole adjuncts to mechanical periodontal treatment [12] . Recently, one study demonstrated a significant reduction in periodontal parameters and inflammatory biomarkers with the use of simvastatin gel and mouthwash in a 1% preparation [13] .

It has been argued that the viral load in the oropharynx and nasopharynx with SARS-CoV-2 infection is as high in asymptomatic patients as those with symptoms [2] .

Assuming that many asymptomatic and even symptomatic patients may seek dental treatment, it is imperative to reduce the viral load in oropharynx through adequate oral prophylactic measures to eliminate or at least to minimize the risk of SARS-CoV-2 transmission to dental personnel and patients.

To achieve this, we suggest: 1) pre-procedural use of mouthwashes and nasal sprays by dental patients, to reduce the risk that any aerosol generating procedures will infect healthcare workers, and 2) use of mouthwashes and nasal sprays by healthcare workers pre-and post-exposure to patients with confirmed or suspected infection to reduce the risk of infection through their mouth or nose. We suggest the following formulation in context of the currently discussed hypothesis: preparation of 1%

Simvastatin mouthwash by dissolving 20 mg simvastatin tablets in distilled water.

Sodium benzoate is added as a preservative followed by glycerin and natural food color and flavor so as its taste will be tolerated. The final preparation will then be J o u r n a l P r e -p r o o f adjusted for its pH by adding triethanolamine solution [13] . In case of considering statins mouthwash, the suggested application time is 15 to 20 seconds [14] .

Thus, given the potential antiviral effect of statins, we hypothesize that the use of topical statins as a mouthwash or even as a nasal spray may minimize the risk of SARS-CoV-2 transmission in dental settings, and hence will protect patients and health care providers during the COVID-19 pandemic and a like. Clinical trials should be considered for this hypothesis. 

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Statins: new American guidelines for prevention of cardiovascular disease

The effects of statins on dental and oral health: a review of preclinical and clinical studies

Lipophilic statins inhibit Zika virus production in Vero cells

Mechanisms of action and efficacy of statins against influenza

Statin therapy in COVID-19 infection

Statins and the COVID-19 main protease: in silico evidence on direct interaction

In-hospital Use of Statins is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Determination of the antibacterial activity of simvastatin against periodontal pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans: an in vitro study

Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin

The effect of statins on periodontal treatment-a systematic review with metaanalyses and meta-regression

Effectiveness of Simvastatin 1% oral gel and mouthwash used as an adjunct treatment of scaling J o u r n a l P r e -p r o o f and root planning in the treatment of periodontal diseases

Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse